Somewhat Positive News Coverage Somewhat Unlikely to Affect Alcobra (ADHD) Share Price

Headlines about Alcobra (NASDAQ:ADHD) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alcobra earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.7822443677619 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern’s rankings:

Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Alcobra from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Roth Capital downgraded shares of Alcobra from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $4.00 to $1.00 in a research report on Friday, September 29th. Finally, WBB Securities raised shares of Alcobra from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research report on Monday, October 9th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $1.50.

Alcobra (NASDAQ ADHD) traded down 4.46% during mid-day trading on Wednesday, reaching $1.50. 230,090 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $1.20 and a 200-day moving average price of $1.14. The stock’s market cap is $41.34 million. Alcobra has a 1-year low of $0.83 and a 1-year high of $2.58.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. Equities research analysts anticipate that Alcobra will post ($0.77) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at

Alcobra Company Profile

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

Insider Buying and Selling by Quarter for Alcobra (NASDAQ:ADHD)

What are top analysts saying about Alcobra Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alcobra Ltd. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit